SEARCH

SEARCH BY CITATION

References

  • Agarwal AK, Monder C.. In vitro metabolism of 7α-methyl-19-nortestosterone by rat liver, prostate, and epididymis: comparison with testosterone and 19-nortestosterone. Endocrinology. 1988; 13: 21872193.
  • Anderson RA, Baird DT. Male contraception. Endocr Rev. 2002;23: 735762.
  • Anderson RA, Irvine DS, Balfour C., Groome NP, Riley SC. Inhibin B in seminal plasma: testicular origin and relationship to spermatogenesis. Hum Reprod. 1998;13: 920926.
  • Anderson RA, Kinniburgh D., Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab. 2002;87: 36403649.
  • Anderson RA, Martin CW, Kung AWC, Everington D., Pun TC, Tan KCB, Bancroft J., Sundaram K., Moo-Young AJ, Baird DT. 7α-Methyl-19-nortestosterone (MENT) maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab. 1999;84: 35563562.
  • Anderson RA, Wallace AM, Sattar N., Kumar N., Sundaram K.. Evidence for tissue selectivity of the synthetic androgen 7alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab. 2003;88: 27842793.
  • Arnlov J., Pencina MJ, Amin S., Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, RB D'Agostino Sr, Bhasin S., Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145: 176184.
  • Brady BM, Walton M., Hollow N., Kicman AT, Baird DT, Anderson RA. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Human Reprod. 2004;19: 26582667.
  • Cummings DE, Kumar N., Bardin CW, Sundaram K., Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7a-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab. 1998;83: 42124219.
  • Grimes D., Gallo M., Grigorieva V., Nanda K., Schulz K.. Steroid hormones for contraception in men. Cochrane Database Syst Rev. 2004; CD004316.
  • Groome NP, Illingworth PJ, O'Brien M., Pai R., Rodger FE, Mather J., McNeilly AS. Measurement of dimeric inhibin B throughout the menstrual cycle. J Clin Endocrinol Metab. 1996;81: 14011405.
  • Handelsman DJ, Conway AJ, Howe CJ, Turner L., Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 1996;81: 41134121.
  • Hougaku H., Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006;290: E234E242.
  • Kamischke A., Heuermann T., Kruger K., vo Eckardstein S., Schellschmidt I., Rubig A., Nieschlag E.. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002;87: 530539.
  • Kamischke A., Nieschlag E.. Progress towards hormonal male contraception. Trends Pharmacol Sci. 2004;25: 4957.
  • Kinniburgh D., Zhu H., Cheng L., Kicman AT, Baird DT, Anderson RA. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Human Reprod. 2002;17: 14901501.
  • Kumar N., Didolkar AK, Ladd A., Thau R., Monder C., Bardin CW, Sundaram K.. Radioimmunoassay of 7α-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. J Steroid Biochem Mol Biol. 1990;37: 587591.
  • LaMorte A., Kumar N., Bardin CW, Sundaram K.. Aromatization of 7alpha-methyl-19-nortestosterone by human placental microsomes in vitro. J Steroid Biochem Mol Biol. 1994;48: 297304.
  • McLachlan RI, O'Donnell L., Stanton PG, Balourdos G., Frydenberg M., de Kretser DM, Robertson DM. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab. 2002;87: 546556.
  • McLachlan RI, Robertson DM, Pruysers E., Ugoni A., Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C.. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab. 2004;89: 142149.
  • Meistrich ML, Wilson G., Zhang Y., Kurdoglu B., Terry NH. Protection from procarbazine-induced testicular damage by hormonal pretreatment does not involve arrest of spermatogonial proliferation. Cancer Res. 1997;57: 10911097.
  • Nieschlag E., Zitzmann M., Kamischke A.. Use of progestins in male contraception. Steroids. 2003;68: 965972.
  • Noé G., Suvisaari J., Martin C., Moo-Young AJ, Sundaram K., Saleh SI, Quintero E., Croxatto HB, Lähteenmäki P.. Gonadotrophin and testosterone suppression by 7a-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Human Reprod. 1999;14: 22002206.
  • Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23: 554566.
  • Shetty G., Weng CC, Meachem SJ, Bolden-Tiller OU, Zhang Z., Pakarinen P., Huhtaniemi I., Meistrich ML. Both testosterone and follicle-stimulating hormone independently inhibit spermatogonial differentiation in irradiated rats. Endocrinology. 2006;147: 472482.
  • Smith JC, Bennett S., Evans LM, Kynaston HG, Parmar M., Mason MD, Cockcroft J.R., Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86: 42614267.
  • Sundaram K., Kumar N., Bardin CW. 7α-methyl-nortestosterone (MENT): the optimal androgen for male contraception. Ann Med. 1993;25: 199205.
  • Suvisaari J., Sundaram K., Noe G., Kumar N., Aguillaume C., Tsong YY, Lähteenmaki P., Bardin CW. Pharmacokinetics and pharmacodynamics of 7α-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum Reprod. 1997;12: 967973.
  • Turner L., Conway AJ, Jimenez M., Liu PY, Forbes E., McLachlan RI, Handelsman DJ. Contraceptive efficacy of a depot progestin and androgen combination in men. Obstet Gynecol Surv. 2004;59: 270271.
  • Vanderschueren D., Vandenput L., Boonen S., Lindberg MK, Bouillon R., Ohlsson C.. Androgens and bone. Endocr Rev. 2004;25: 389425.
  • Venken K., Boonen S., van Herck E., Vandenput L., Kumar N., Sitruk-Ware R., Sundaram K., Bouillon R., Vanderschueren D.. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone. 2005;36: 663670.
  • vo Eckardstein S., Noe G., Brache V., Nieschlag E., Croxatto H., Alvarez F., Moo-Young A., Sivin I., Kumar N., Small M., Sundaram K.. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88: 52325239.
  • Walton M., Anderson RA, Kicman AT, Elton RA, Ossowska K., Baird DT. A diurnal variation in testicular hormone production is maintained following gonadotrophin suppression in normal men. Clin Endocrinol. 2006;65: 123129.
  • Organization World Health. WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction. Cambridge, United Kingdom: Cambridge University Press; 1999.
  • World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336: 955959.
  • World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65: 821829.